Alx Oncology Holdings  share price logo

Alx Oncology Holdings 

NASDAQ: ALXO

Small Cap

$1.69

-0.01

(-0.59%)

as on

Alx Oncology Holdings  Stock Performance

as on May 2, 2026 at 6:59 am IST

  • Day's High

    $1.69
    $1.91

    13.02%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $0.40
    $2.66
    downward going graph

    76.09%

    Downside

    57.40%

    Upside

    downward going graph

Alx Oncology Holdings  share price movements today

Previous Close
$1.70
Open
$1.71
Volume
2.1M
Day's Low - High
$1.69 - $1.91
52 Week Low - High
$0.40 - $2.66

Alx Oncology Holdings  Historical Returns

1 Month Return
-14.21 %
3 Month Return
-15.92 %
1 Year Return
+ 217.13 %
3 Year Return
-73.39 %
5 Year Return
-97.3 %

Alx Oncology Holdings  Stock Fundamentals & Key Indicators

Check Alx Oncology Holdings  market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$227.4M

EPS (TTM)

-0.6493

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-100.1M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-145.70%

Alx Oncology Holdings  vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Alx Oncology Holdings  with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$227.4M-97.3%NA0.00%
BUY$39.5B125.06%74.5912.55%
BUY$107.8B97.31%27.7132.94%
NA$32.7BNA118.975.37%
BUY$73.5B44.57%17.1229.65%

Stock Returns calculator for Alx Oncology Holdings  Stock including INR - Dollar returns

The Alx Oncology Holdings  stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Alx Oncology Holdings  investment value today

Current value as on today

₹3,59,024

Returns

₹2,59,024

(+259.02%)

Returns from Alx Oncology Holdings  Stock

₹2,18,868 (+218.87%)

Dollar Impact

₹40,156 (+40.16%)

Analyst Recommendation on Alx Oncology Holdings  Stock

Based on 13 analysts

BUY

84.62%

Buy

15.38%

Hold

0.00%

Sell

Based on 13 analysts, 84.62% of analysts recommend a 'BUY' rating for Alx Oncology Holdings . Average target price of $4.6

Alx Oncology Holdings  Share Price Target

Get share price movements and forecasts by analysts on Alx Oncology Holdings .

What analysts predicted

63.26%UPSIDE

Target Price

$4.6

Current Price

$1.69

Analyzed by

13 Analysts

Target

$4.60

Alx Oncology Holdings  target price $4.6, a slight upside of 63.26% compared to current price of $1.69. According to 13 analysts rating.

Alx Oncology Holdings  Stock’s Investor Sentiment and Interest

Search interest for Alx Oncology Holdings  Stock has decreased by -12% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-12% versus previous 30 day period

Alx Oncology Holdings  Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
-
2
-
-
-
0
-
-
-
-
Gross Profit
0
0
0
0
0
0
0
0
-
-
Operating Income
-53
-48
-37
-41
-32
-30
-31
-26
-22
-23
EBITDA
-50
-44
-34
-38
-30
-28
-30
-25
-21
-23
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-50
-45
-35
-39
-30
-29
-30
-25
-22
-22
Income Tax Expense
0
1
0
-
-
-
-
-
-
-
Net Income
-50
-45
-35
-39
-30
-29
-30
-25
-22
-22
Net Profit Margin
0.00%
-1833.55%
0.00%
0.00%
0.00%
-3359.79%
0.00%
0.00%
0.00%
0.00%

Alx Oncology Holdings  Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
2
4
1
-
-
-
-
-
Gross Profit
0
0
0
0
-1
0
0
-
Operating Income
-13
-19
-43
-83
-127
-170
-142
-100
EBITDA
-13
-18
-43
-83
-127
-158
-132
-100
Interest Expense
-
0
0
0
4
1
1
1
Depreciation
0
0
0
0
0
0
0
0
Income Before Tax
-13
-19
-45
-83
-123
-160
-134
-101
Income Tax Expense
0
0
0
0
0
-
-
-
Net Income
-13
-19
-45
-83
-123
-160
-134
-101
Net Profit Margin
-664.30%
-401.23%
-3869.71%
0.00%
0.00%
0.00%
0.00%
0.00%

Alx Oncology Holdings  Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-45
-35
-39
-30
-29
-30
-25
-22
-22
Operating Cash Flow
-39
-37
-26
-25
-32
-24
-23
-17
-18
Investing Cash Flow
-16
26
0
25
33
27
22
21
11
Financing Cash Flow
59
3
27
0
0
0
0
0
0
Change in Cash
2
-8
1
0
1
3
-1
4
-7

Alx Oncology Holdings  Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-19
-45
-83
-123
-160
-134
-101
Operating Cash Flow
-14
-38
-68
-89
-130
-121
-84
Investing Cash Flow
0
0
-4
-235
44
86
82
Financing Cash Flow
15
462
2
9
59
30
0
Change in Cash
0
425
-70
-314
-26
-4
-1

Global Institutional Holdings in Alx Oncology Holdings 

Funds
Holdings
Bank of Montreal
0.35%
Almitas Capital LLC
3.87%
Northern Trust Corp
0.11%
Ameriprise Financial Inc
0.5%
Seven Fleet Capital Management LP
0.09%

Insights on Alx Oncology Holdings 

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, ALXO has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, ALX ONCOLOGY HOLDINGS INC has experienced a drawdown of -73.4%, however Alnylam Pharmaceuticals, Inc. resisted the overall trend and outperformed by 66.4%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, ALXO stock has moved down by -14.2%

About Alx Oncology Holdings 

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
OrganisationAlx Oncology Holdings 
Headquarters323 Allerton Avenue, South San Francisco, CA, United States, 94080
IndustryBiotechnology
CEOMr. Jason W. Lettmann
E-voting on sharesClick here to vote

Key Management of Alx Oncology Holdings 

Name

Title

Ms. Lisa Sauer

Senior Vice President of Regulatory Affairs & Quality Assurance

Ms. Sue Naim

Senior Vice President of Clinical Operations

Mr. Harish Shantharam C.F.A.

Chief Financial Officer

Dr. Barbara J. Klencke M.D.

Chief Medical Officer

Mr. Jeff E. Knight M.P.H.

Chief Development & Operating Officer

Dr. Athanasios Tsiatis M.D.

Senior Vice President of Clinical Development

Dr. Lin Yeong-Liang M.D., M.S.

Senior Vice President of Drug Safety & Pharmacovigilance

Mr. Jason W. Lettmann

CEO & Director

Ms. Shelly Wong CPA

Senior VP of Finance & Chief Accounting Officer

Ms. Venita De Almeida Ph.D.

VP & Head of Research Program Development

FAQs

What is Alx Oncology Holdings  share price today?

Alx Oncology Holdings  share price today is $1.69 as on at the close of the market. Alx Oncology Holdings  share today touched a day high of $1.91 and a low of $1.69.

What is the 52 week high and 52 week low for Alx Oncology Holdings  share?

Alx Oncology Holdings  share touched a 52 week high of $2.66 on and a 52 week low of $0.4 on . Alx Oncology Holdings  stock price today i.e. is closed at $1.69,which is 36.47% down from its 52 week high and 318.32% up from its 52 week low.

What is Alx Oncology Holdings 's market capitalisation today?

Alx Oncology Holdings  market capitalisation is $0.00T as on .

How to invest in Alx Oncology Holdings  Stock (ALXO) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Alx Oncology Holdings  on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Alx Oncology Holdings  Shares that will get you 0.8876 shares as per Alx Oncology Holdings  share price of $1.69 per share as on May 2, 2026 at 1:29 am IST.

What is the minimum amount required to buy Alx Oncology Holdings  Stock (ALXO) from India?

Indian investors can start investing in Alx Oncology Holdings  (ALXO) shares with as little as ₹94.91 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.10 in Alx Oncology Holdings  stock (as per the Rupee-Dollar exchange rate as on ). Based on Alx Oncology Holdings  share’s latest price of $1.69 as on May 2, 2026 at 1:29 am IST, you will get 5.9172 shares of Alx Oncology Holdings . Learn more about fractional shares .

What are the returns that Alx Oncology Holdings  has given to Indian investors in the last 5 years?

Alx Oncology Holdings  stock has given -97.3% share price returns and 28.57% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?